Controversy and scrutiny surrounding Humacyte have primarily centered on the slow velocity of initial commercial adoption for its breakthrough tissue products, regulatory review timelines, and the financial pressures typical of early-stage biotech firms. Market debates often focus on balancing the revolutionary medical promise of universally implantable bioengineered vessels against the substantial capital expenditures and dilution risks faced by public retail shareholders.